Cargando…

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019

A 78‐year‐old Japanese woman with no smoking history suffered from near‐fatal coronavirus disease 2019 (COVID‐19) requiring four‐week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Hiroaki, Nakagawa, Taisuke, Sakoda, Soichiro, Ishimatsu, Akiko, Taguchi, Kazuhito, Kadowaki, Masako, Moriwaki, Atsushi, Yoshida, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008274/
https://www.ncbi.nlm.nih.gov/pubmed/33815804
http://dx.doi.org/10.1002/rcr2.744
_version_ 1783672662539632640
author Ogata, Hiroaki
Nakagawa, Taisuke
Sakoda, Soichiro
Ishimatsu, Akiko
Taguchi, Kazuhito
Kadowaki, Masako
Moriwaki, Atsushi
Yoshida, Makoto
author_facet Ogata, Hiroaki
Nakagawa, Taisuke
Sakoda, Soichiro
Ishimatsu, Akiko
Taguchi, Kazuhito
Kadowaki, Masako
Moriwaki, Atsushi
Yoshida, Makoto
author_sort Ogata, Hiroaki
collection PubMed
description A 78‐year‐old Japanese woman with no smoking history suffered from near‐fatal coronavirus disease 2019 (COVID‐19) requiring four‐week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high‐flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post‐COVID‐19 fibrosis, although further studies are warranted.
format Online
Article
Text
id pubmed-8008274
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-80082742021-04-02 Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019 Ogata, Hiroaki Nakagawa, Taisuke Sakoda, Soichiro Ishimatsu, Akiko Taguchi, Kazuhito Kadowaki, Masako Moriwaki, Atsushi Yoshida, Makoto Respirol Case Rep Case Reports A 78‐year‐old Japanese woman with no smoking history suffered from near‐fatal coronavirus disease 2019 (COVID‐19) requiring four‐week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high‐flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post‐COVID‐19 fibrosis, although further studies are warranted. John Wiley & Sons, Ltd 2021-03-30 /pmc/articles/PMC8008274/ /pubmed/33815804 http://dx.doi.org/10.1002/rcr2.744 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Ogata, Hiroaki
Nakagawa, Taisuke
Sakoda, Soichiro
Ishimatsu, Akiko
Taguchi, Kazuhito
Kadowaki, Masako
Moriwaki, Atsushi
Yoshida, Makoto
Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title_full Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title_fullStr Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title_full_unstemmed Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title_short Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
title_sort nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008274/
https://www.ncbi.nlm.nih.gov/pubmed/33815804
http://dx.doi.org/10.1002/rcr2.744
work_keys_str_mv AT ogatahiroaki nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT nakagawataisuke nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT sakodasoichiro nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT ishimatsuakiko nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT taguchikazuhito nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT kadowakimasako nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT moriwakiatsushi nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019
AT yoshidamakoto nintedanibtreatmentforpulmonaryfibrosisaftercoronavirusdisease2019